BIVV009
Total Payments
$160,832
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $160,832 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $160,832 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 1 SAFETY, TOLERABILITY, AND PHARMACOKINETICS & PHARMACODYNAMICS STUDY OF MULTIPLE-DOSE BIVV009 IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) | BIOVERATIV THERAPEUTICS INC. | $160,832 | 0 |
Top Doctors Receiving Payments for BIVV009
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $160,832 | 6 |
Ad
Manufacturing Companies
- BIOVERATIV THERAPEUTICS INC. $160,832
Product Information
- Type Drug
- Total Payments $160,832
- Total Doctors 0
- Transactions 6
About BIVV009
BIVV009 is a drug associated with $160,832 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is BIOVERATIV THERAPEUTICS INC..
Payment data is available from 2019 to 2019. In 2019, $160,832 was paid across 6 transactions to 0 doctors.
The most common payment nature for BIVV009 is "Unspecified" ($160,832, 100.0% of total).
BIVV009 is associated with 1 research study, including "A PHASE 1 SAFETY, TOLERABILITY, AND PHARMACOKINETICS & PHARMACODYNAMICS STUDY OF MULTIPLE-DOSE BIVV009 IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)" ($160,832).